Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states.

The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states.

The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

The present invention provides aqueous ophthalmic formulations containing 0.01%-5% by weight of cyclosporine which exists in the form of micelles having a particle size not greater than 20 nm, and methods of making and using such formulations.

Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administration to a subject. Such compositions display improved bioavailability and pharmacokinetics relative to compositions that comprise the hydrophobic bioactive molecules instead of the anions.

Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administration to a subject. Such compositions display improved bioavailability and pharmacokinetics relative to compositions that comprise the hydrophobic bioactive molecules instead of the anions.

Devices, systems, and methods for use in managing treatment of a chronic disorder with pharmaceutical or therapeutic compounds by tracking symptoms associated with the disorder. Methods include inputting patient attributes, factors and various and other data relating to the patient in conjunction with one or more symptoms into a symptom tracking system and outputting a report of the data tracked over time to any of the patient, a medical professional and a drug developer to improve identification of a relapse of the chronic condition and improve management of the treatment regimen for any and all patients.

Devices, systems, and methods for use in managing treatment of a chronic disorder with pharmaceutical or therapeutic compounds by tracking symptoms associated with the disorder. Methods include inputting patient attributes, factors and various and other data relating to the patient in conjunction with one or more symptoms into a symptom tracking system and outputting a report of the data tracked over time to any of the patient, a medical professional and a drug developer to improve identification of a relapse of the chronic condition and improve management of the treatment regimen for any and all patients.

Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administering to the lungs of a subject, by inhalation, a composition comprising an effective amount of an active agent such as a corticosteroid (for example, loteprednol etabonate (LE)). Also provided are pharmaceutical compositions comprising an active agent, such as a corticosteroid (for example, loteprednol etabonate (LE)) in an amount effective to treat, minimize and/or substantially inhibit inflammation associated with the respiratory virus, such as COVID-19 and/or ARDS.

Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administering to the lungs of a subject, by inhalation, a composition comprising an effective amount of an active agent such as a corticosteroid (for example, loteprednol etabonate (LE)). Also provided are pharmaceutical compositions comprising an active agent, such as a corticosteroid (for example, loteprednol etabonate (LE)) in an amount effective to treat, minimize and/or substantially inhibit inflammation associated with the respiratory virus, such as COVID-19 and/or ARDS.

An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.